|
|
Kiryat Weizmann Science Park, Bldg. 7, P.O. Box 2313
Rehovot, 76123 Israel
phone:972-8-9385100
fax:972-8-9300795
|
|
| Symbol |
Public |
| Exchange |
TASE |
| Founded |
1993 |
| Employees |
|
|
|
| www.dpharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Lipid-based drugs for the treatment of brain disorders. |
|
| Management |
| Dr. Alexander Kozak, Founder, Chief Executive Officer and President; Dr. Gilad Rosenberg, Vice President for Clinical Development; Peter Geffen, Quality Assurance and Regulatory Affairs Manager; Ofra Yamin, VP Finance & Human Resources; Andrea Klainer, Corporate Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| lipid-based, brain disorder, stroke, Epilepsy, pre-clinical, neuro-degenerative, CNS, Alzheimer's disease |
|
|
|
| Description |
|
D-Pharm is focused on the discovery and development of innovative lipid-based drugs for the treatment of the most devastating brain disorders. |
|
| Products / Services |
The company has two products in advanced clinical development (Phase II): DP-b99 for Stroke; and DP-VPA for Epilepsy. In addition, the Company possesses a substantial pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders and cancer. The most advanced of these candidates are DP-109 and DP-155, both for the treatment of Alzheimer's disease.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
